Senores Pharmaceuticals (SENORES.NS) Earnings Analysis
Senores Pharmaceuticals (SENORES.NS) next reports earnings on 2026-07-27, consensus EPS 5.81 INR. Last quarter (2026-05-14) it beat with EPS 6.9 INR vs 6.29 INR est (+9.7%). It has beaten estimates in 2/2 recent quarters (100%). Trailing P/E 52.69.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SENORES.NS next report earnings?
| Next earnings date | 2026-07-27 |
|---|---|
| Consensus EPS estimate | 5.81 INR |
| Revenue estimate | 1.93B |
SENORES.NS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 6.9 INR | 6.29 INR | +9.7% | Beat |
| 2026-01-20 | 6.9 INR | 6.12 INR | +12.7% | Beat |
Beat rate: 2/2 (100%) over reported quarters with consensus data.
SENORES.NS valuation and analyst view
| Trailing P/E | 52.69 |
|---|---|
| Trailing EPS | 29.055 INR |
| Price / book | 5.91 |
| Dividend yield | 0.00% |
| Market cap | 64.17B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Senores Pharmaceuticals (SENORES.NS)'s next earnings date?
Senores Pharmaceuticals is next scheduled to report on 2026-07-27, with a consensus EPS estimate of 5.81 INR and revenue estimate of 1.93B.
Did SENORES.NS beat earnings last quarter?
In its 2026-05-14 report, SENORES.NS posted EPS of 6.9 INR versus a 6.29 INR estimate — a beat of 9.7%.
What is SENORES.NS's earnings track record?
Over the last 2 reported quarters with consensus data, SENORES.NS beat estimates 2 times (100%).
What is SENORES.NS's current P/E ratio and EPS?
SENORES.NS trades at a trailing P/E of 52.69 on trailing EPS of 29.05488156887295 INR.
What do analysts rate SENORES.NS?
SENORES.NS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.